Supplements

Black cohosh: plant identity, menopausal symptom evidence, extract and blend differences, conflicting findings, and liver-safety reports

6 sources · Latest source check 2026-10-13 UTC

On this page

Black cohosh is Actaea racemosa, also called Cimicifuga racemosa. Its roots and underground stems are used in preparations promoted for menopausal symptoms. Benefit remains uncertain and findings conflict. It differs from blue cohosh, another botanical with its own serious risks. A similar common name does not identify an equivalent exposure.[1]

Plant parts, extracts and outcomes differ

Plant parts, extracts and outcomes differ
Term	Meaning
Root / rhizome	Root and underground-stem material used in preparations.[2]
Standardized extract	A named marker amount, not guaranteed efficacy.[2]
Vasomotor symptoms	Hot flashes and night sweats.[4]
Multi-herb preparation	An exposure with more than black cohosh alone.[3]

Extraction and marker amounts do not prove interchangeability

NIH ODS describes powders, liquid extracts and dried extracts with considerable chemical variation. The constituents responsible for any clinical benefit are not established. A listed triterpene-glycoside amount describes one preparation feature; it cannot certify that all formulations share the same effect. Product reformulation also matters when comparing old and current evidence.[2]

An estrogen-like marketing claim does not establish how the plant works

ODS describes uncertain mechanisms, including proposed hormonal and brain-related actions. Evidence that a product affects a laboratory pathway does not establish symptom relief, protection against disease or safety after hormone-sensitive cancer. A mechanism claim and a clinical trial answer different questions.[2]

The newer review pooled a broader set of preparations

Sadahiro and colleagues’ 2023 pairwise meta-analysis included 22 articles with information on 2,310 menopausal women. It assessed black-cohosh extracts alone or combined with other active ingredients. The selected original indexed methods and findings reported significant improvements in overall symptoms and hot flashes compared with placebo.[3]

A favorable blend result cannot isolate one botanical

Including combination preparations broadens the question. Their findings cannot independently identify black cohosh’s contribution, and pooling symptom scales does not establish identical benefit for every individual symptom or extract. Complete product-level subgroup, risk-of-bias, effect-precision and sponsor-role appraisal remains outstanding.[3]

The review is evidence, rather than an exhaustive search through 2026

The publication supplies a dated synthesis of selected trials. Its result needs comparison with negative studies and other reviews, which may share underlying experiments. Counting each review as a new independent replication would overstate the amount of evidence.[3]

The herbal regimens did not outperform placebo

Hot-flash frequency, intensity and the symptom-subscale result generally did not differ between herbal interventions and placebo. One later intensity comparison was worse for the mixture-plus-soy group. Hormone therapy reduced symptoms in this selected population; that comparator result does not choose treatment for someone with different risks or eligibility.[4]

An association does not provide an individual risk percentage

The selected agency overview and indexed hepatotoxicity passages were inspected, rather than every original case report. These reports identify a safety concern but do not supply a reliable risk per supplement user. Current-batch identity and detailed clinical causality remain important gaps.[5]

Cancer, pregnancy and symptom type require separate questions

NCCIH describes uncertainty after breast cancer or in hormone-sensitive conditions, and concern during pregnancy and breastfeeding. The agency’s discussion of the newer review does not identify improvement in anxiety or depression. A menopause total score cannot establish treatment of a psychiatric condition or safety in these distinct clinical settings.[1]

An incompletely studied interaction is not a guarantee of safety

ODS states that clinically relevant medicine interactions were not established in its account, while acknowledging the lack of systematic study. That limitation does not certify every multi-ingredient product or medication combination. The actual constituents and clinical context still matter.[2]

Vasomotor symptoms have a narrower meaning than menopause symptoms

Vasomotor symptoms mean hot flashes and night sweats. They are not the same endpoint as vaginal dryness, depressed mood, sleep difficulty or a combined menopause-symptom score. The2023 society statement evaluates treatments specifically for vasomotor symptoms. A preparation that changes a broad questionnaire might still fail to reduce the frequency of hot flashes. Conversely, an unsuccessful hot-flash trial does not directly answer every possible use of the plant.[6]

A prescribing recommendation asks more than whether any study was positive

The2023 statement did not recommend black cohosh for vasomotor symptoms because evidence of benefit was insufficient. It noted uncertain active constituents and mechanisms, older placebo-controlled findings and studies of different Cimicifuga species or combinations. That recommendation and the favorable pooled results discussed earlier can differ because their selected studies, formulations and endpoints differ. This is a substantive disagreement about dependable clinical benefit, rather than evidence that every product works or that no person can experience symptom relief.[6]

Evidence & uncertainty

A 2023 meta-analysis reported favorable symptom findings; a substantial one-year trial found no meaningful herbal advantage over placebo. Products, mixtures and outcomes differ. The findings need reconciliation rather than one verdict for every black-cohosh preparation.[3][4]

Selected-source overview · Independent review pending

Published questions

Are black cohosh and blue cohosh the same botanical?

Selected-source overview · Independent review pending. Read the evidence context.

They are different plants.[1]

Evidence behind this answer

Black Cohosh: Usefulness and Safety
agency condition or prevention explanation · 2024
Selected relevant original official page passages inspected · November 2024 update: identity, blue-cohosh distinction, purpose-specific evidence and safety gaps